Results Presentation
Fiscal 2022 Second Quarter

協和キリン株式会社

Agenda

Financial Review
Commercial Update
R&D Update
News Flow in 2022

President and Chief Executive Officer Masashi Miyamoto, Ph.D.

Q&A

President and Chief Executive Officer Masashi Miyamoto, Ph.D.
Managing Executive Officer, Head of Finance Motohiko Kawaguchi
Executive Officer, Head of R&D Yoshifumi Torii, Ph.D.
Executive Officer, Head of Global Product Strategy, Strategy Division Tomohiro Sudo

This document contains certain forward-looking statements relating to such items as the company's (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasonable assumptions made by the company in making its forecasts, but the actual results in practice may differ substantially due to uncertain factors.

These uncertain factors include, but are not limited to, potential risks of the business activities in the pharmaceutical industry in Japan and overseas, intellectual property risks, risk of side effects, regulatory risks, product defect risks, risks of changes to the prices for raw materials, risks of changes to market prices, as well as risks of changes to foreign exchange rates and financial markets.

This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.

Financial Review

Summary of Q2 Results

(Billion Yen / Rounded)

	2021Q2 Results	2022Q2 Results	Changes	2022 Revised Plans	Progresses
Revenue *[Overseas Ratio]*	165.0 *[52%]*	185.3 *[59%]*	+20.2 (+12%)	380.0→ 400.0 *[62%]*	46%
Gross Profit *[Gross Profit Margin]*	123.8 *[75%]*	141.9 *[77%]*	+18.1 (+15%)	298.0→ 312.0 *[78%]*	45%
SG&A *[SG&A Ratio]*	67.2 *[41%]*	76.4 *[41%]*	+9.2 (+14%)	164.0→ 172.0 *[43%]*	44%
R&D *[R&D Ratio]*	26.5 *[16%]*	27.9 *[15%]*	+1.4 (+5%)	70.0→ 67.0 *[17%]*	42%
Gain/Loss on Equity Method	0.9	2.4	+1.5 (+158%)	3.0→ 4.0	59%
Core Operating Profit *[Core OP Margin]*	30.9 *[19%]*	39.9 *[22%]*	+9.0 (+29%)	67.0→ 77.0 *[19%]*	52%
Profit	25.1	35.0	+9.9 (+40%)	53.0→ 63.0	56%

YoY Analysis -Revenue-

+20.2 billion yen
(incl. forex effect +9.8)



- **Japan -3.9**
  Although Duvroq, Romiplate, G-Lasta, and Crysvita increased, revenue in Japan region decreased by 5% due mainly to negative impact by NHI price-cut in April 2021 & April 2022 and shrink in Patanol for which generic products entered the market last December.

- **North America +12.9 (incl. forex effect +5.2)**
  Revenue in North America region increased by 37% with the growth of Crysvita, Poteligeo, and Nourianz.

- **EMEA +5.0 (incl. forex effect +2.1)**
  Growth of Crysvita and Poteligeo contributed to the 19% increase in EMEA region, although Abstral fell due to generic products' penetration.

- **APAC +0.5 (incl. forex effect +1.2)**
  APAC revenue increased by 3% with the growth of Gran, Neulasta, Nesp, etc, while Regpara was down due to the Chinese national tender system.

- **Other +5.7 (incl. forex effect +1.2)**
  42% growth in the other revenue was contributed by the deferred revenue of USD400M upfront payment from KHK4083 partnership, that was initiated from last July, and royalties of growing Fasenra (Benralizumab).

Revenue of Major Items (Japan)

(Billion Yen / Rounded)

Item	2021Q2 Results	2022Q2 Results	Changes	Reasons	2022 Rev. Plans	Progresses
Nesp + Nesp-AG[1]	12.9	10.5	-2.4 (-19%)	NHI price-cut & Biosimilars' penetration	19.5→ 20.7	51%
Nesp	1.9	1.6	-0.3 (-14%)		3.1→ 3.3	50%
Nesp-AG	11.0	8.8	-2.2 (-20%)		16.4→ 17.4	51%
Duvroq	0.5	2.7	+2.1 (+391%)	Market penetration (Launched in Aug 2020)	5.5→ 5.9	46%
Regpara	1.5	1.1	-0.3 (-23%)		2.4→ 2.0	56%
Orkedia	4.6	4.9	+0.3 (+6%)		10.0→ 10.4	47%
G-Lasta	13.8	14.8	+1.0 (+7%)	Market's recovery & penetration	31.5→ 31.5	47%
Poteligeo	0.9	1.0	+0.0 (+4%)		1.9→ 2.0	49%
Rituximab BS	5.3	5.0	-0.2 (-4%)	NHI price-cut	9.7→ 10.3	49%
Romiplate	2.8	4.8	+1.9 (+68%)	Recovery from supply constraints from Jun 2020 through Mar 2021	10.0→ 10.0	48%
Allelock	4.8	3.8	-1.0 (-21%)	Generics' penetration & NHI price-cut	6.6→ 5.6	69%
Patanol	7.8	2.2	-5.6 (-72%)	Generics entered in Dec 2021	3.9→ 3.0	72%
Nouriast	4.2	3.9	-0.3 (-7%)	Competitors' penetration	8.4→ 8.1	48%
Haruropi	1.3	1.8	+0.4 (+33%)	Market penetration (Launched in Dec 2019)	5.5→ 4.1	43%
Crysvita	3.3	4.1	+0.8 (+23%)	Market penetration (Launched in Dec 2019)	10.0→ 9.2	45%
Tech-licensing	1.3	0.4	-0.9 (-70%)	Deferred process of FKB[2]-related upfront revenue completed	1.0→ 0.9	43%

1 AG stands for Authorized Generic. Official product name is Darbepoetin Alfa [KKF]. Kyowa Kirin Frontier is a marketing authorization holder; Kyowa Kirin is a distributor.
2 FKB stands for Fujifilm Kyowa Kirin Biologics Co., Ltd.

Revenue of Major Items (ex-Japan)

(Billion Yen / Rounded)

Item	2021Q2 Results	2022Q2 Results	Changes	Reasons	2022 Rev. Plans	Progresses
Crysvita	35.4	49.4	+14.0 (+40%)	[North America] Market penetration [EMEA] Geographical expansion & Additional indication (Adult) [APAC] Launched in China	105.2→ 116.2	43%
North America	25.7	35.9	+10.1 (+39%)			
EMEA	9.7	13.5	+3.8 (+39%)			
APAC	–	0.1	+0.1 (–)			
Poteligeo	7.0	10.3	+3.3 (+47%)	[North America] Market penetration [EMEA] Geographical expansion & Market penetration	22.5→ 23.6	44%
North America	5.8	8.1	+2.3 (+40%)		15.0→ 18.1	45%
EMEA	1.1	2.1	+1.0 (+87%)		7.6→ 5.5	39%
Nourianz	1.9	2.6	+0.7 (+34%)	Market penetration	6.6→ 6.1	42%
Abstral	4.0	3.6	-0.4 (-11%)	Generic's penetration	6.7→ 7.2	50%
Regpara	4.6	2.0	-2.6 (-57%)	Listed on Chinese tender list[1] in Oct 2021	3.7→ 3.8	52%
Tech-licensing	9.1	15.3	+6.2 (+68%)	Deferred revenue of KHK4083 upfront payment (July 2021-) & Growth of Fasenra	34.3→ 35.0	44%
Benralizumab Royalty[2]	7.1	9.3	+2.1 (+30%)			

*1 Volume-Based Procurement (VBP) program that has been introduced since 2018 for reducing healthcare cost in China. A few companies are selected as a supplier through a tender, while their drug prices dramatically drop down.
*2 Sales royalties of Fasenra which has been marketed by AstraZeneca, including our own estimation.
＊ Revenue from Early Access Program (EAP) are not included in the figures above.

YoY Analysis -Core OP-

+9.0 billion yen
(incl. forex effect +3.7)



- **Gross Profit +18.1 (incl. forex effect +9.1)**
  Increased in conjunction with JPY20.2B rise in revenue. Margin improved by 1.6% (75.0%→76.6%) because there was a big negative impact related to elimination of intercompany profits on inventories last year.

- **SG&A -9.2 (incl. forex effect -4.2)**
  Increased by aggressive investment in IT/Digital infrastructure and human resources for the maximization of the global 3 brands (G3B) and the early consolidation of global business foundation, in addition to Crysvita profit sharing expenses for North America.
  [Labor -5.2 / Sales promotion -4.1 (incl. Crysvita profit sharing expenses -3.8) / Depreciation & Amortization +0.2 / Other -0.1]

- **R&D -1.4 (incl. forex effect -1.2)**
  Clinical study costs of mainly ME-401 and KHK4083/AMG 451 increased.

- **Gain/Loss on Equity Method +1.5**
  FKB recorded additional deferred tax asset.

FKB; Fujifilm Kyowa Kirin Biologics Co., Ltd.

YoY Analysis -Profit-

Profit (Jan-Jun) +9.9 billion yen



Summary of FY2022 Revised Plan

(Billion Yen / Rounded)

	2022 Full Year Original Plans	2022H1 Results	2022H2 Revised Plans	2022 Full Year Revised Plans	Changes
Revenue *[Overseas Ratio]*	380.0 *[59%]*	185.3 *[59%]*	214.7 *[65%]*	400.0 *[62%]*	+20.0 (+5%)
Gross Profit *[Gross Profit Margin]*	298.0 *[78%]*	141.9 *[77%]*	170.1 *[79%]*	312.0 *[78%]*	+14.0 (+5%)
SG&A *[SG&A Ratio]*	164.0 *[43%]*	76.4 *[41%]*	95.6 *[44%]*	172.0 *[43%]*	-8.0 (+5%)
R&D *[R&D Ratio]*	70.0 *[18%]*	27.9 *[15%]*	39.1 *[18%]*	67.0 *[17%]*	+3.0 (-4%)
Gain/Loss on Equity Method	3.0	2.4	1.6	4.0	+1.0 (+33%)
Core Operating Profit *[Core OP Margin]*	67.0 *[18%]*	39.9 *[22%]*	37.1 *[17%]*	77.0 *[19%]*	+10.0 (+15%)
Profit	53.0	35.0	28.0	63.0	+10.0 (+19%)

FY2022 Original Plan vs Revised Plan

Profit (Jan-Dec) +10.0 billion yen



Commercial Update

Crysvita

(Billion Yen)



* Excludes EAP patients and patients who have not started reimbursement process

2022 Key Actions & Q2 Topics

Key Actions

- North America: Initiate full-scale preparation for transfer of commercialization planned in spring 2023.
- EMEA: Continue to focus on geographical & indication expansion. TIO review to be completed.

Q2 Topics

- North America: Re-outbreak of Covid-19 from end-2021 thru early-2022 got subsided and business went steadily. Preparations for the transfer are proceeding as planned.
- EMEA: Launched in Latvia for Pediatric XLH. Obtained positive opinion for TIO indication from CHMP.

Launched Countries/ Regions as of June 30, 2022

Excluding Latin America

Underlines: Pediatric and Adult / Bolded types: New launches in Q2 2022

2018	USA , Germany, Netherland, Luxembourg
2019	Canada, England, Wales, Northern Ireland, Slovakia, Sweden, Israel, UAE, Czech, Denmark, Italy, Japan, Norway, Bahrain, Austria
2020	Scotland, Oman, Kuwait, Qatar, Romania, Slovenia, France, Finland, Estonia, Spain
2021	Ireland, Hungary, Belgium, Saudi Arabia, Hong Kong, China, Singapore
2022	Portugal, **Latvia**

Poteligeo

(Billion Yen)



* Excludes EAP patients and patients who have not started reimbursement process

2022 Key Actions & Q2 Topics

Key Actions

- EMEA: Continue to talk with payers to ensure reimbursement and patient access to product.
- US/EMEA: Work with Healthcare professionals to gather and share evidence such as clinical data in association of blood tumor burden to help understand better use of Poteligeo.

Q2 Topics

- US: Communication with HCPs is continuing to increase due to easing of Covid-19 restrictions.
- EMEA: Launched in France and Czech Republic. Steadily growing as we expand into new markets (plus forex impact), leading to an 87% growth vs the previous year.

Launched Countries/ Regions as of Jun 30, 2022

Bolded types: New launches in Q2 2022

2012	Japan
2018	USA
2020	Germany, Austria, Luxembourg
2021	Italy, Scotland, Netherland, Belgium, Slovenia, Denmark, Spain, Finland
2022	Sweden, Saudi Arabia, Slovakia, England, Wales, Northern Ireland, **France, Czech**

Nourianz

(Billion Yen)



2022 Key Actions & Q2 Topics

Key Actions

- North America: Focus on approaching potential prescribers and get their deeper understanding of the features of Nourianz such as safety, convenience, and novel mode of action.

Q2 Topics

- North America: Behind the original plan due to the tough market situation with competitors, while revenue is growing consistently. F2F communication with HCPs on the rise. Continuing promotional activities appealing Nourianz's features for HCPs/patients.

Launched Countries/ Regions as of March 31, 2022

2013 Japan
2019 USA

R&D Update

Upcoming Events: Next-generation Strategic Products

✓ : Completed events from May 11, 2022, to Aug 4, 2022

Code Generic Name	Event	Time Expected	Month Completed
KHK4083/AMG 451 rocatinlimab	**Atopic dermatitis P3 FPI** (enrollment paused) ✓	Mid-2022	Jun-2022
KW-6356	Parkinson's disease P3 FPI Parkinson's disease P2b detailed data	Discontinued H2 2022	
ME-401 zandelisib	CLL (combo, 2L+) P2 FPI **FL (mono, 3L+) P2 detailed data*** ✓ iB-NHL (mono, 3L+) P2 topline data (JP)	H2 2022 Mid-2022 H2 2022	Jun-2022
RTA 402 bardoxolone methyl	Diabetic kidney disease P3 LPO	H2 2022	
KHK7791 tenapanor	Hyperphosphatemia under maintenance dialysis submission (JP)	H2 2022	

*: a more detailed report of the P2 TIDAL data reported on Nov. 30, 2021 was presented at ASCO2022 and EHA2022; FPI: first patient in; LPO: last patient out; CLL: chronic lymphocytic leukemia; FL: follicular lymphoma; iB-NHL: indolent B-cell non-Hodgkin lymphoma

Update: Rocatinlimab (KHK4083/AMG 451)
Ph3 ROCKET Program Amendment

- The ROCKET Phase 3 program was initiated in June 2022.
- However, following additional discussions with regulators and our partner, we are amending the studies to improve patient convenience and investigate a range of doses.
- No safety or efficacy issues have arisen.

Update: Other pipelines whose development plans have changed

KW-6356: Development discontinuation

- Based on communication with the regulatory authorities, we concluded that it would be difficult to achieve its target product profile which we had aimed for.
- We decided to discontinue KW-6356's development after a thorough evaluation of the global regulatory landscape, development hurdles, and timelines for potential market entry.

RTA 402 (ADPKD)：Extending the term of the Ph3 FALCON study

- Based on the review regarding Alport Syndrome in CRDAC[1] of FDA in December 2021 and others, Reata held a Type A meeting with FDA regarding protocol changes of the FALCON study including extending the term of the study in 2022 2Q.
- Expected year of first approval is currently under scrutiny.

1. Cardiovascular and Renal Drugs Advisory Committee

News Flow in 2022

Year-to-date Key News Flow ①

AS of August 4, 2022

Category	Date	Headline
ESG	Jan 11	Introduction of Renewable Energy “Aqua Premium” for Fuji Research Park and CMC R&D Center
LCM	Jan 31	NDA submission of Topical Ophthalmic Mitomycin C Agent（Japan）
LCM	Feb 25	Approval for Partial Change of Approved Indication of G-Lasta（Japan） (for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Allogenic Blood Stem Cell Transplantation)
ESG	Mar 9	Selection as “Health & Productivity Stock” for the First Time（Japan）
R&D	Mar 31	Regulatory Update on Zandelisib Following Meeting with the FDA
LCM	Apr 4	Publication of Safety Data from a Clinical Trial of Automated Injection Device of G-Lasta（Japan）
SCM	May 17	Construction of a New Biopharmaceutical API Manufacturing Building at Takasaki Plant
R&D	May 18	Joint Research Agreement with LUCA Science on mitochondrial disease treatment with novel mitochondria modality
R&D	May 31	Achievement of First Milestone in Research Collaboration with InveniAI
LCM	Jun 1	Positive Data from Phase 3 Study of Lumicef in Systemic Sclerosis (EULAR 2022 Congress)

Updates after the previous earnings announcement

ESG: environmental, social, and governance; LCM: lifecycle management

Year-to-date Key News Flow ②

AS of August 4, 2022

Category	Date	Headline
R&D	Jun 5	New Clinical Data on Zandelisib (American Society of Clinical Oncology Annual Meeting)
R&D	Jun 10	Clinical Data on Zandelisib (European Hematology Association 2022 Hybrid Congress)
LCM	Jun 27	Positive CHMP Opinion for Use of Crysvita for TIO
R&D	Jul 15	Discontinuation of Developing KW-6356
R&D	Jul 19	Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy (The Lancet Oncology)
LCM	Aug 1	Approval of “G-Lasta Subcutaneous Injection 3.6mg BodyPod” in Japan

Updates after the previous earnings announcement

ESG: environmental, social, and governance; LCM: lifecycle management

Appendix

FOREX Information

Average FOREX Rates (yen)

	2021Q2	2022Q2	Changes	2022 Rev. Plans
USD/JPY	107	120	+13	128
GBP/JPY	147	158	+11	162

Q2 YoY FOREX Impacts (billion yen)

	Revenue	Core OP
USD/JPY	+6.3	+2.4
GBP/JPY	+2.1	+0.5

FY2022 FOREX Sensitivities (billion yen)

	Changes	Revenue	Core OP
USD/JPY	+1 yen	+1.1	+0.3
GBP/JPY	+1 yen	+0.4	+0.1

Crysvita - Collaboration with Ultragenyx -

	Economic Terms
US & Canada	• Kyowa Kirin books sales • 50/50 profit share for 5 years from the U.S. launch • After 5 years, Kyowa Kirin pays tiered sales royalties in mid-high 20% range to Ultragenyx • Supply price: 35% of net sales through 2022, 30% thereafter
Europe	• Kyowa Kirin books sales • Kyowa Kirin pays sales royalties in up to 10% range to Ultragenyx *Ultragenyx has sold a royalty right from 2020 onwards to Royalty Pharma
Latin America	• Ultragenyx books sales • Kyowa Kirin receives low single-digit sales royalties from Ultragenyx • Supply price: 35% of net sales through 2022, 30% thereafter
Turkey	• Ultragenyx books sales • Kyowa Kirin receives sales royalties in up to 20% range from Ultragenyx
Asia & Others	• Kyowa Kirin books sales

* Kyowa Kirin supplies commercial products in all territories.

KHK4083/AMG 451 - Collaboration with Amgen -

	US	Europe & Asia (ex. JP)	JP
Development	• Amgen leads development • Share development cost	• Amgen leads development • Share development cost	• Kyowa Kirin leads development
Commercialization	• Amgen commercializes and books sales • Kyowa Kirin co-promotes and shares promotion cost	• Amgen commercializes and books sales • Kyowa Kirin has opt-in rights for co-promotion	• Kyowa Kirin commercializes and books sales
Sales Royalties	• Double-digit royalty to Kyowa Kirin	• Double-digit royalty to Kyowa Kirin	
Commercial supply	• Amgen supplies	• Amgen supplies	• Kyowa Kirin supplies

Amgen makes a $400 million up-front payment (done) and future contingent milestone payments potentially worth up to an additional $850 million, as well as royalty payments on future global sales, to Kyowa Kirin.

Development Plan of Next-generation Strategic Products

T : Topline data　D : Detailed data　As of Aug 4, 2022



*: Japan; **: a more detailed report of the P2 TIDAL data reported on Nov. 30, 2021 was presented at ASCO2022 and EHA2022; MA: marketing application; FL: follicular lymphoma; MZL: marginal zone lymphoma; iB-NHL: indolent B-cell non-Hodgkin's lymphoma; CLL: chronic lymphocytic leukemia; ADPKD: autosomal dominant polycystic kidney disease; 3L+: third-line or later therapy ; 2L+: second-line or later therapy

Estimated Patient Numbers

Disease	Country/ Region	Incidence	Prevalence*	Reference
ATL	JP	1,150 / y		Survey and countermeasures to HTLV-1 infection and related diseases in Japan. 2009 summary research report (Yamaguchi, 2010)
PTCL	JP		2,000	Ministry of Health, Labour and Welfare: 2017 Patient survey (illness classification)
CTCL	JP		2,000	Ministry of Health, Labour and Welfare: 2017 Patient survey (illness classification)
	US	1,500 / y		SEER Data (2001-2007)
XLH	JP	1:20,000	Adult: 5,000 Ped: 1,000	Estimate based on reported prevalence of 1 in 20,000 people; Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. (Endo I et al., Endocr J., 2015)
	EU	1:20,000	Adult: 12,000 Ped: 3,000	Estimate based on reported prevalence of 1 in 20,000 people
	US	1:20,000	Adult: 12,000 Ped: 3,000	Estimate based on reported prevalence of 1 in 20,000 people; New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. (Carpenter TO, Pediatr Clin North Am., 1997)
TIO	JP		30	2010 Ministry of Health, Labour and Welfare Epidemiological Research on abnormalities in Hormone Receptor Mechanisms
	US		500-1,000	Survey by Ultragenyx Pharmaceutical
AD	JP, NA, EU		30,000,000	Study by Decision Resources
PD	JP		162,000	Ministry of Health, Labour and Welfare: 2017 Patient survey (illness classification)
	US	60,000 / y	~1,000,000	Cited from Parkinson's Foundation https://www.parkinson.org/Understanding-Parkinsons/Statistics Accessed February 7, 2022.
FL	US	15,000 / y		Cited from Cancer.net https://www.cancer.net/ Accessed February 7, 2022.
	JP	6,750 / y		Cited from Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry) and Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan (Miyoshi H et al., Int J Hematol, 2018)
MZL	US	6,000 / y		Cited from Lymphoma.org https://lymphoma.org/ Accessed February 7, 2022.
	JP	1,060 / y		Cited from Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry) and Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan (Miyoshi H et al., Int J Hematol, 2018)
AS	JP		1,200	Cited from the website of Japan Intractable Diseases Information Center https://www.nanbyou.or.jp/entry/4348 Accessed February 7, 2022.
ADPKD	JP		31,000	Cited from the website of Japan Intractable Diseases Information Center https://www.nanbyou.or.jp/entry/295 Accessed February 7, 2022.
CKD	JP		13,300,000	Japanese Society of Nephrology, Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease (2012)
CKD (Dialysis)	JP	40,885 / y	344,640	The Japanese Society for Dialysis Therapy, An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2019)

*Prevalence represents the estimated patient number per the entire population of each country or region.

List of Acronyms

AD	Atopic Dermatitis
ADPKD	Autosomal Dominant Polycystic Kidney Disease
AG	Authorized Generic
AS	Alport Syndrome
ATL	Adult T-Cell Leukemia/Lymphoma
BS	Biosimilar
CKD	Chronic Kidney Disease
CLL	Chronic Lymphocytic Leukemia
DKD	Diabetic Kidney Disease
FL	Follicular Lymphoma
iB-NHL	Indolent B-cell Non-Hodgkin’s Lymphoma
LCM	Lifecycle Management
MZL	Marginal Zone Lymphoma
PD	Parkinson’s Disease
PTCL	Peripheral T-Cell Lymphoma
TIO	Tumor Induced Osteomalacia
XLH	X-linked Hypophosphatemia

Kyowa Kirin Co., Ltd.
Corporate Communications Dept., IR Group
+81-3-5205-7206 / ir@kyowakirin.com